



Syngene

Putting Science to Work

PRESS RELEASE

Syngene International Signs R&D Agreement with GSK

Syngene scientists to work with GSK to advance drug discovery
in multiple therapeutic areas

26 March 2018, Bangalore, India

Syngene International, a leading global contract research services company, today announced an R&D agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms.

As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists, will work closely with GSK's global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world's most pressing healthcare needs.

Syngene started offering Discovery services to global R&D focused organizations from 1994 onwards. Over the years, the Company has consolidated its leadership position in offering integrated discovery, development and manufacturing services across small and large molecules within both the pharmaceutical and biotechnology industries.

Commenting on the collaboration, **Jonathan Hunt, Chief Executive Officer, Syngene International**, said, " *We are very proud to add a world class scientific organization like GSK to our growing list of strategic partners. The collaboration in many ways underlines Syngene's position as one of the most innovative, capable and cost effective providers of discovery research services to the global pharma industry. GSK is a global industry leader and we believe Syngene's scientific capabilities and expertise will complement GSK's efforts to discover and develop new medicines to benefit patients worldwide.*"

About Syngene

Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is India's largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides. It brings together a state-of-the-art infrastructure spread across 1.3 Mn sq. ft and a highly experienced team of over 3100 scientists,

Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science



PRESS RELEASE

to help R&D focused organizations improve their efficiency and reduce product development time. In FY2017, Syngene serviced 293 clients including 8 of the top 10 global pharma companies as well as industry leaders in segments like biotechnology, nutrition, animal health, consumer goods and specialty chemicals. For more details, visit www.syngeneintl.com.

For further information, please reach out to:

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com